Powered by

RedShiftBio Appoints Julien Bradley as CEO and Closes $18M Series D Round Funding; New CEO and additional funding come as installations of its AQS3pro(TM) platform gain momentum at leading biopharmaceutical customers in US and Europe

Jan 29, 2020 - Business Wire
Board and Executive Moves-Investments

RedShift BioAnalytics, Inc. (RedShiftBio), a provider of innovative analytical solutions for protein characterization used in biotherapeutic drug development, is pleased to announce the appointment of Julien Bradley as Chief Executive Officer. The appointment is a key part of the company's strategy for accelerated growth following the successful launch of the AQS3pro(TM), a novel platform filling a critical gap in protein characterization during drug development. RedShiftBio recently completed t...